OTTAWA, May 6 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or
"the Company") today announced the provision of its lead cancer drug
PhG-alpha-1 to the Ottawa Hospital Research Institute ("OHRI") for
commencement of testing.
The focus of this round of testing, first announced on March 24, 2009,
will be on the effect of PhG-alpha-1 on cancer cell growth rate, mobility and
invasion characteristics, using a panel of nine ovarian cancer cell lines. Of
the OHRI cell lines being tested, two are also included in the 60 cell line
panel used at the National Cancer Institute ("NCI") in Bethesda MD, (testing
of the PharmaGap drug at the NCI has previously been announced). OHRI
Researchers under the direction of Dr. Barbara Vanderhyden will assess the
potency of PharmaGap's drug compound both as a single agent therapeutic and in
combination with the current standard of care chemotherapeutic drug used to
treat ovarian cancer. Previous testing at PharmaGap and at Memorial Sloan
Kettering Cancer Centre in New York has demonstrated that PhG-alpha-1 has been
observed to provide superior effects when administered in combination with
available chemotherapeutic agents. The broad range of ovarian cell lines at
the OHRI expands the potential for positive results in the overall test
program for PhG-alpha-1.
The drug compound provided to OHRI is from the second batch of compound
produced by CS Bio of Menlo Park, CA, under contract with PharmaGap. Batch
production of drug compound at CS Bio is continuing in order to ensure that
the Company has a sufficient and consistent supply for all testing programs in
"We are excited to see the test program at Dr. Vanderhyden's lab begin,
and are pleased that she and her research team have agreed to bring their
expertise to bear in furthering our drug development program for PhG-alpha-1",
said Robert McInnis, President and C.E.O. of PharmaGap. "Combined with
expected results from testing at the NCI and with all previous test programs
completed, we hope to see conclusive, independently derived proof of efficacy
for PhG-alpha-1 that will attract the attention of both the pharmaceutical
industry and the investment community in Canada and the United States."
The results of the test program at OHRI are expected to be available in
the third quarter of 2009.
About the Ottawa Hospital Research Institute
The OHRI is the research arm of The Ottawa Hospital and is an affiliated
institute of the University of Ottawa. The OHRI is one of the largest
hospital-based research institutes in Canada, with more than 1,400
researchers, trainees and support staff, $90 million in funding and thousands
of patients involved in over 600 ongoing clinical research studies. For more
information please visit www.ohri.ca.
About Dr. Barbara Vanderhyden
Dr. Vanderhyden is a Senior Scientist, Cancer Therapeutics at the OHRI
and a Professor in the Departments of Cellular & Molecular Medicine and
Obstetrics & Gynecology at the University of Ottawa. She holds the Corinne
Boyer Chair in Ovarian Cancer Research. She has published over 60 peer
reviewed journal papers primarily in the area of ovarian cancer and
collaborates extensively with many pharmaceutical and biotechnology companies
focused on the development of therapies for ovarian cancer.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel therapeutic compounds for the
treatment of cancer. PharmaGap's research platform targets cellular signalling
pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug
compound, PhG-alpha-1, is in preclinical development. The Company's strategy
is to out-license drug compounds to larger life sciences companies at the
preclinical stage. For more information on PharmaGap please visit the
Company's website at www.pharmagap.com.
Note: The TSX-Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has approved or
disapproved of the information contained herein. This release contains
forward looking statements that may not occur or may change materially.
For further information:
For further information: Robert McInnis, President & CEO, (613)